• Chart
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs
    1. Home
    2. Stocks
    3. Vaishali Share Price

    Vaishali Pharma Share PriceVaishali Pharma

    Small Cap Result
    ₹141.3
    -0.75 (-0.53%)
    As on 03 December, 2023 | 05:37 BSE: NSE: VAISHALIISIN: INE972X01014

    Vaishali Pharma Performance

    Day Range

    • Low 141.00
    • High 147.00
    ₹ 141.3

    52 Week Range

    • Low 114.85
    • High 193.75
    ₹ 141.3
    • Open Price142.35
    • Previous Close142.05
    • Volume148803

    Start SIP in Vaishali Pharma

    Start SIP

    Vaishali Pharma Share Price

    • Over 1 Month 2.17%
    • Over 3 Month 12.72%
    • Over 6 Month 3.78%
    • Over 1 Year 12.86%

    Vaishali Pharma Key Statistics

    P/E Ratio 23.4
    PEG Ratio 1.2
    Market Cap Cr 150
    Price to Book Ratio 3.7
    EPS 6.2
    Dividend 0
    Relative Strength Index 58.64
    Money Flow Index 66.46
    MACD Signal 1.05
    Average True Range 5.67

    Vaishali Pharma Investment Rating

    • Master Rating:

    • Vaishali Pharma has an operating revenue of Rs. 72.31 Cr. on a trailing 12-month basis. An annual revenue de-growth of -7% needs improvement, Pre-tax margin of 13% is healthy, ROE of 16% is good. The company has a reasonable debt to equity of 13%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 200DMA and around 5% above its 50DMA. It needs to stay above the 200DMA levels to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 85 which is a GOOD score indicating consistency in earnings, a RS Rating of 33 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 73 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Vaishali Pharma Financials
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 13132620131022
    Operating Expenses Qtr Cr 1011251711825
    Operating Profit Qtr Cr 3214321
    Depreciation Qtr Cr 0000000
    Interest Qtr Cr 0010111
    Tax Qtr Cr 1101110
    Net Profit Qtr Cr 2203220
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 7278
    Operating Expenses Annual Cr 6169
    Operating Profit Annual in Cr 97
    Depreciation Cr 10
    Interest Annual Cr 22
    Tax Annual Cr 22
    Net Profit Annual Cr 74
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 1
    Cash from Investing Activity Annual Cr -1
    Cash from Financing Annual Activity Cr 0
    Net Cash Flow Annual Cr 1
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 4126
    Fixed Assets Annual Cr 32
    Total Non Current Assets Annual Cr 65
    Total Current Assets Annual Cr 7376
    Total Assets Annual Cr 7982
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 3825
    ROE Annual % 1615
    ROCE Annual % 2328
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 1611
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr
    Operating Expenses Qtr Cr
    Operating Profit Qtr Cr
    Depreciation Qtr Cr
    Interest Qtr Cr
    Tax Qtr Cr
    Net Profit Qtr Cr
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr
    Operating Expenses Annual Cr
    Operating Profit Annual in Cr
    Depreciation Cr
    Interest Annual Cr
    Tax Annual Cr
    Net Profit Annual Cr
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr
    Cash from Investing Activity Annual Cr
    Cash from Financing Annual Activity Cr
    Net Cash Flow Annual Cr
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr
    Fixed Assets Annual Cr
    Total Non Current Assets Annual Cr
    Total Current Assets Annual Cr
    Total Assets Annual Cr
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs
    ROE Annual %
    ROCE Annual %
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin %
    Invest in Vaishali Pharma

    Vaishali Pharma Technicals

    EMA & SMA

    Current Price
    ₹141.3
    -0.75 (-0.53%)
    pointer
    • Bullish Moving Average
    • ___
    • 16
    • Bearish Moving Average
    • ___
    • 0
    • 20 Day
    • ₹137.86
    • 50 Day
    • ₹135.34
    • 100 Day
    • ₹133.82
    • 200 Day
    • ₹130.80
    • 20 Day
    • ₹137.67
    • 50 Day
    • ₹134.20
    • 100 Day
    • ₹131.67
    • 200 Day
    • ₹137.10

    Vaishali Pharma Resistance and Support

    PIVOT
    ₹143.1
    Resistance
    First Resistance 145.20
    Second Resistance 149.10
    Third Resistance 151.20
    RSI 58.64
    MFI 66.46
    MACD Single Line 1.05
    MACD 1.47
    Support
    First Resistance 139.20
    Second Resistance 137.10
    Third Resistance 133.20

    Vaishali Pharma Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 148,803 7,148,496 48.04
    Week 128,823 6,465,601 50.19
    1 Month 47,056 2,641,232 56.13
    6 Month 104,040 5,714,911 54.93

    Vaishali Pharma Result Highlights

    Vaishali Pharma Synopsis

    NSE-Medical-Diversified

    Vaishali Pharma is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 69.66 Cr. and Equity Capital is Rs. 10.55 Cr. for the Year ended 31/03/2023. Vaishali Pharma Ltd. is a Public Limited Listed company incorporated on 25/03/2008 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L52310MH2008PLC181632 and registration number is 181632.
    Market Cap 150
    Sales 72
    Shares in Float 0.77
    No of funds
    Yield
    Book Value 3.68
    U/D Vol ratio 1.1
    LTDebt / Equity 13
    Alpha 0.06
    Beta 0.29

    Vaishali Pharma

    Owner NameSep-23Jun-23Mar-23Dec-22
    Promoters 26.62%26.74%26.74%26.74%
    Mutual Funds
    Insurance Companies
    Foreign Portfolio Investors
    Financial Institutions/ Banks
    Individual Investors 62%65.97%64.92%62.85%
    Others 11.38%7.29%8.34%10.41%

    Vaishali Pharma Management

    Name Designation
    Mr. Atul Vasani Chairman & Managing Director
    Mr. Dewansh Vasani Executive Director
    Mrs. Jagruti Vasani Whole Time Director
    Mr. Ashvin Ganatra Independent Director
    Mr. Manish Ved Independent Director
    Mr. Pratik Jakhelia Independent Director

    Vaishali Pharma Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Vaishali Pharma Corporate Action

    Date Purpose Remarks
    2023-05-22 Audited Results
    2022-11-03 Quarterly Results
    2022-07-25 Quarterly Results
    2022-05-30 Audited Results
    2022-05-04 Others To consider raising of funds issue in the ratio of 3:5 of Rs. 10/-

    Vaishali Pharma FAQs

    What is Share Price of Vaishali Pharma ?

    Vaishali Pharma share price is ₹141 As on 03 December, 2023 | 05:23

    What is the Market Cap of Vaishali Pharma ?

    The Market Cap of Vaishali Pharma is ₹149.7 Cr As on 03 December, 2023 | 05:23

    What is the P/E ratio of Vaishali Pharma ?

    The P/E ratio of Vaishali Pharma is 23.4 As on 03 December, 2023 | 05:23

    What is the PB ratio of Vaishali Pharma ?

    The PB ratio of Vaishali Pharma is 3.7 As on 03 December, 2023 | 05:23

    Q2FY23

    More Information

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI REGN No.: ARN-104096 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support desk helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
    ©2023, 5Paisa Capital Ltd. All Rights Reserved.
    We are ISO 27001:2013 Certified.